Alimera Sciences Inc  

(Public, NASDAQ:ALIM)   Watch this stock  
Find more results for ALIM
-0.07 (-1.40%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.79 - 5.09
52 week 4.12 - 6.54
Open 4.93
Vol / Avg. 93,596.00/144,103.00
Mkt cap 219.10M
P/E     -
Div/yield     -
EPS -0.89
Shares 44.35M
Beta 1.33
Inst. own 94%
Jun 8, 2015
Alimera Sciences Inc Annual Shareholder Meeting (Estimated) Add to calendar
May 6, 2015
Q1 2015 Alimera Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 25, 2015
Alimera Sciences Inc Analyst and Investor Luncheon
Mar 4, 2015
Q4 2014 Alimera Sciences Inc Earnings Call
Mar 4, 2015
Q4 2014 Alimera Sciences Inc Earnings Release
Mar 2, 2015
Alimera Sciences Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -531.76% -426.33%
Operating margin -627.23% -396.38%
EBITD margin - -383.33%
Return on average assets -36.64% -55.66%
Return on average equity - -
Employees 105 -
CDP Score - -


6120 Windward Pkwy Ste 290
ALPHARETTA, GA 30005-8897
United States - Map
+1-678-9905740 (Phone)
+1-678-9905744 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alimera Sciences, Inc. is a biopharmaceutical company. The Company researches, develops and commercializes the prescription of ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye. The Company�s product is ILUVIEN, an implant providing a therapeutic effect for up to 36 months in the treatment of vision impairment associated with chronic diabetic macular edema (DME) by delivering sustained sub-microgram levels of Fluocinolone Acetonide (FAc), a non-proprietary corticosteroid. ILUVIEN consists of a tiny polyimide tube with a membrane cap. ILUVIEN is inserted in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. ILUVIEN is approved for chronic DME in the United Kingdom and European Union. ILUVIEN is also studied in three Phase II clinical trials for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD and retinal vein occlusion (RVO).

Officers and directors

Philip R. Tracy J.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
C. Daniel Myers President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Richard S. Eiswirth Jr. Chief Financial Officer, Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Kenneth Green Ph.D. Senior Vice President, Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
David R Holland Senior Vice President - Sales and Marketing
Age: 50
Bio & Compensation  - Reuters
Philip Ashman Senior Vice President, European Managing Director
Age: 49
Bio & Compensation  - Reuters
Susan Caballa Senior Vice President - Regulatory and Medical Affairs
Age: 69
Bio & Compensation  - Reuters
Brian K. Halak Ph.D. Independent Director
Bio & Compensation  - Reuters
James R. Largent Independent Director
Age: 64
Bio & Compensation  - Reuters
Calvin W. Roberts M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters